CN101481675A - 一种抗猪瘟多表位dna疫苗及构建方法和应用 - Google Patents
一种抗猪瘟多表位dna疫苗及构建方法和应用 Download PDFInfo
- Publication number
- CN101481675A CN101481675A CNA2009100604316A CN200910060431A CN101481675A CN 101481675 A CN101481675 A CN 101481675A CN A2009100604316 A CNA2009100604316 A CN A2009100604316A CN 200910060431 A CN200910060431 A CN 200910060431A CN 101481675 A CN101481675 A CN 101481675A
- Authority
- CN
- China
- Prior art keywords
- dna
- rns
- swine fever
- ptpas
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010037660 Pyrexia Diseases 0.000 title claims abstract description 74
- 108010041986 DNA Vaccines Proteins 0.000 title claims abstract description 53
- 229940021995 DNA vaccine Drugs 0.000 title claims abstract description 53
- 238000010276 construction Methods 0.000 title claims abstract description 10
- 241000282898 Sus scrofa Species 0.000 claims abstract description 74
- 101100466198 Mus musculus Ptpra gene Proteins 0.000 claims abstract description 45
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 claims abstract description 37
- 239000012634 fragment Substances 0.000 claims abstract description 26
- 241000282887 Suidae Species 0.000 claims abstract description 13
- 241000588724 Escherichia coli Species 0.000 claims abstract description 8
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 4
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 4
- 108020004414 DNA Proteins 0.000 claims description 65
- 239000013612 plasmid Substances 0.000 claims description 57
- 238000011238 DNA vaccination Methods 0.000 claims description 30
- 239000002773 nucleotide Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 27
- 239000007788 liquid Substances 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 24
- 241000710778 Pestivirus Species 0.000 claims description 21
- 238000002156 mixing Methods 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 20
- 239000006228 supernatant Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 238000013016 damping Methods 0.000 claims description 16
- 239000012530 fluid Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 230000000890 antigenic effect Effects 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 238000012360 testing method Methods 0.000 claims description 15
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 13
- 238000000746 purification Methods 0.000 claims description 13
- 238000005406 washing Methods 0.000 claims description 13
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 12
- 238000011081 inoculation Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 238000001976 enzyme digestion Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 238000012408 PCR amplification Methods 0.000 claims description 8
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 8
- 238000013467 fragmentation Methods 0.000 claims description 8
- 238000006062 fragmentation reaction Methods 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000000284 extract Substances 0.000 claims description 7
- 230000004927 fusion Effects 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 108091026890 Coding region Proteins 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000002699 waste material Substances 0.000 claims description 6
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 102000012410 DNA Ligases Human genes 0.000 claims description 4
- 108010061982 DNA Ligases Proteins 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 4
- 108090000364 Ligases Proteins 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 claims description 3
- 238000002123 RNA extraction Methods 0.000 claims description 3
- 108091028664 Ribonucleotide Proteins 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 235000018102 proteins Nutrition 0.000 claims description 3
- 239000002336 ribonucleotide Substances 0.000 claims description 3
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 3
- -1 5 μ l Substances 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 108010047524 Deoxyribonuclease HindIII Proteins 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000013611 chromosomal DNA Substances 0.000 claims description 2
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical class CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 238000010839 reverse transcription Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 29
- 241000700605 Viruses Species 0.000 abstract description 17
- 230000003053 immunization Effects 0.000 abstract description 16
- 238000002649 immunization Methods 0.000 abstract description 16
- 210000002966 serum Anatomy 0.000 abstract description 16
- 108091007433 antigens Proteins 0.000 abstract description 14
- 239000000427 antigen Substances 0.000 abstract description 12
- 102000036639 antigens Human genes 0.000 abstract description 11
- 238000001514 detection method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 5
- 241000710777 Classical swine fever virus Species 0.000 abstract description 3
- 230000008030 elimination Effects 0.000 abstract description 3
- 238000003379 elimination reaction Methods 0.000 abstract description 3
- 238000005138 cryopreservation Methods 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 55
- 239000002574 poison Substances 0.000 description 21
- 231100000614 poison Toxicity 0.000 description 21
- 239000000523 sample Substances 0.000 description 14
- 238000001890 transfection Methods 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 238000010369 molecular cloning Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 101710194807 Protective antigen Proteins 0.000 description 9
- 108010020567 12E7 Antigen Proteins 0.000 description 8
- 239000000020 Nitrocellulose Substances 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 102000008482 12E7 Antigen Human genes 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 6
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003292 glue Substances 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 206010008631 Cholera Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000036760 body temperature Effects 0.000 description 5
- 238000000197 pyrolysis Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000011960 computer-aided design Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229960004756 ethanol Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000011330 nucleic acid test Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229940031551 inactivated vaccine Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000003314 quadriceps muscle Anatomy 0.000 description 2
- 238000012207 quantitative assay Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 241000405758 Betapartitivirus Species 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 208000001726 Classical Swine Fever Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010059484 Haemodilution Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 101800004910 Nuclease A Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical class [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
检测样品 | OD492(Mean±SD) |
ptPAs/ΔE2/ΔErns转染PK细胞裂解液 | 0.533±0.020 |
ptPAs/ΔE2/ΔErns转染PK细胞上清液 | 0.722±0.026 |
pVAX1转染PK细胞裂解液 | 0.216±0.010 |
pVAX1转染PK细胞上清液 | 0.245±0.010 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100604316A CN101481675B (zh) | 2009-01-06 | 2009-01-06 | 一种抗猪瘟多表位dna疫苗及构建方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100604316A CN101481675B (zh) | 2009-01-06 | 2009-01-06 | 一种抗猪瘟多表位dna疫苗及构建方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101481675A true CN101481675A (zh) | 2009-07-15 |
CN101481675B CN101481675B (zh) | 2011-09-14 |
Family
ID=40878965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100604316A Active CN101481675B (zh) | 2009-01-06 | 2009-01-06 | 一种抗猪瘟多表位dna疫苗及构建方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101481675B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934076A (zh) * | 2010-08-11 | 2011-01-05 | 武汉大学 | 非传播抗猪瘟和乙脑基因工程双价标记减毒活疫苗及应用 |
CN102586209A (zh) * | 2012-03-15 | 2012-07-18 | 济南诺能生物工程有限公司 | 一种液体耐高温酸性甘露聚糖酶的制作方法 |
CN103933581A (zh) * | 2014-05-04 | 2014-07-23 | 贵州大学 | 一种基于csf-fmd二联基因工程疫苗的制备方法 |
CN111093699A (zh) * | 2017-07-12 | 2020-05-01 | Nouscom股份公司 | 用于治疗癌症的新抗原疫苗组合物 |
CN111848786A (zh) * | 2020-07-29 | 2020-10-30 | 中牧实业股份有限公司 | 一种单克隆抗体、其制备方法及用途 |
-
2009
- 2009-01-06 CN CN2009100604316A patent/CN101481675B/zh active Active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101934076A (zh) * | 2010-08-11 | 2011-01-05 | 武汉大学 | 非传播抗猪瘟和乙脑基因工程双价标记减毒活疫苗及应用 |
CN101934076B (zh) * | 2010-08-11 | 2012-08-08 | 武汉大学 | 非传播抗猪瘟和乙脑基因工程双价标记减毒活疫苗及应用 |
CN102586209A (zh) * | 2012-03-15 | 2012-07-18 | 济南诺能生物工程有限公司 | 一种液体耐高温酸性甘露聚糖酶的制作方法 |
CN102586209B (zh) * | 2012-03-15 | 2013-08-07 | 济南诺能生物工程有限公司 | 一种液体耐高温酸性甘露聚糖酶的制作方法 |
CN103933581A (zh) * | 2014-05-04 | 2014-07-23 | 贵州大学 | 一种基于csf-fmd二联基因工程疫苗的制备方法 |
CN111093699A (zh) * | 2017-07-12 | 2020-05-01 | Nouscom股份公司 | 用于治疗癌症的新抗原疫苗组合物 |
CN111848786A (zh) * | 2020-07-29 | 2020-10-30 | 中牧实业股份有限公司 | 一种单克隆抗体、其制备方法及用途 |
Also Published As
Publication number | Publication date |
---|---|
CN101481675B (zh) | 2011-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103314103B (zh) | 猪第二型环状病毒、含彼的免疫组合物、检测套组及其应用 | |
CN101833005B (zh) | 一种用于检测非洲猪瘟病毒抗体的竞争elisa试剂盒 | |
CN101900731B (zh) | 一种区别检测猪瘟疫苗免疫与野毒感染抗体的elisa试剂盒及其制备方法 | |
CN101825633B (zh) | 用于检测非洲猪瘟病毒的竞争elisa试剂盒 | |
CN105331636A (zh) | 一种稳定表达猪瘟病毒e2蛋白的重组细胞系及其应用 | |
CN103751774A (zh) | 稳定表达猪瘟病毒e2蛋白的重组细胞系及其在制备猪瘟亚单位疫苗和诊断试剂中的应用 | |
CN107937349A (zh) | 稳定表达非洲猪瘟病毒p54蛋白的细胞系及其制备与应用 | |
CN101481675B (zh) | 一种抗猪瘟多表位dna疫苗及构建方法和应用 | |
CN104293741A (zh) | 一种呼吸道合胞病毒病毒样颗粒疫苗及其制备方法和应用 | |
Ivanov et al. | Vaccination with viral protein-mimicking peptides postpones mortality in domestic pigs infected by African swine fever virus | |
CN109182380A (zh) | 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用 | |
CN110029116B (zh) | 一种分泌表达多抗原表位猪瘟病毒e2基因的重组病毒及制备方法与应用 | |
CN102221618B (zh) | 猪瘟兔化弱毒标记疫苗毒株的构建及疫苗的制备方法 | |
CN102321639A (zh) | 基孔肯雅病毒病毒样颗粒的制备方法和应用 | |
CN109880838A (zh) | 一种分泌表达猪o型口蹄疫病毒多表位基因的重组病毒及其制备方法和应用 | |
CN103360498B (zh) | 一种抗鸡传染性法氏囊病的重组蛋白亚单位疫苗 | |
Sakoda et al. | Development and evaluation of indirect enzyme-linked immunosorbent assay for a screening test to detect antibodies against classical swine fever virus | |
CN107723281B (zh) | 表达猪圆环病毒2型Cap蛋白的重组猪瘟兔化弱毒疫苗株及其应用 | |
CN105859842A (zh) | A型口蹄疫病毒单克隆抗体识别的中和表位及其应用 | |
CN105348386B (zh) | 抗口蹄疫o型病毒的单克隆抗体组合及检测试剂盒 | |
CN102747092B (zh) | 表达o型口蹄疫病毒空衣壳的重组缺损腺病毒及其应用 | |
CN105296434B (zh) | 杂交瘤细胞株及其分泌的抗口蹄疫o型病毒的单克隆抗体与应用 | |
CN103539839A (zh) | 肠道病毒71型的vp2抗原的中和表位多肽及其用途 | |
CN102735807B (zh) | 一种鸭出血性卵巢炎灭活疫苗的效力检验方法 | |
CN102533798B (zh) | 表达a型口蹄疫病毒空衣壳重组腺病毒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHANGSHU ZIJIN INTELLECTUAL PROPERTY SERVICE CO., Free format text: FORMER OWNER: WUHAN UNIVERSITY Effective date: 20121219 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430072 WUHAN, HUBEI PROVINCE TO: 215500 SUZHOU, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121219 Address after: 215500 Changshou City South East Economic Development Zone, Jiangsu, Jin Road, No. 8 Patentee after: Changshu Zijin Intellectual Property Service Co., Ltd. Address before: 430072 Hubei city of Wuhan province Wuchang Luojiashan Patentee before: Wuhan University |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160525 Address after: 518052 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A (located in Shenzhen Qianhai business secretary Co. Ltd.) Patentee after: Qianhai Shenzhen Sino Swiss Biological Technology Co., Ltd. Address before: 215500 Changshou City South East Economic Development Zone, Jiangsu, Jin Road, No. 8 Patentee before: Changshu Zijin Intellectual Property Service Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20171130 Address after: 213133 Jiangsu province Xinbei District of Changzhou City Luo Xi Zhen Sheng Da Lu Airport Industrial Park No. 19 Patentee after: Changzhou same Thai biopharmaceutical Polytron Technologies Inc Address before: 518052 Guangdong city of Shenzhen province Qianhai Shenzhen Hong Kong cooperation zone before Bay Road No. 1 building 201 room A (located in Shenzhen Qianhai business secretary Co. Ltd.) Patentee before: Qianhai Shenzhen Sino Swiss Biological Technology Co., Ltd. |
|
TR01 | Transfer of patent right |